Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2022-04-10T23:53:04Z | - |
dc.date.available | 2022-04-10T23:53:04Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF PHARMACEUTICS, v. 605, Page. 2021-2033 | en_US |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0378517321006219 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/169834 | - |
dc.description.abstract | Anticancer regimens have been substantially enriched through monoclonal antibodies targeting immune checkpoints, programmed cell death-1/programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4. Inconsistent clinical efficacy after solo immunotherapy may be compensated by nanotechnology- driven combination therapy. We loaded human serum albumin (HSA) nanoparticles with paclitaxel (PTX) via nanoparticle albumin-bound technology and pooled them with anti-PD-L1 monoclonal antibody through a pH- sensitive linker for targeting and immune response activation. Our tests demonstrated satisfactory preparation of paclitaxel-loaded, PD-L1-targeted albumin nanoparticles (PD-L1/PTX@HSA). They had small particle size (~200 nm) and polydispersity index (~0.12) and successfully incorporated each constituent. Relative to normal physiological pH, the formulation exhibited higher drug-release profiles favoring cancer cell-targeted release at low pH. Modifying nanoparticles with programmed cell death-ligand 1 increased cancer cell internalization in vitro and tumor accumulation in vivo in comparison with non-PD-L1-modified nanoparticles. PD-L1/PTX@HSA constructed by nanoparticle albumin-bound technology displayed successful tumor inhibition efficacy both in vitro and in vivo. There was successful effector T-cell infiltration, immunosuppressive programmed cell death- ligand 1, and regulatory T-cell suppression because of cytotoxic T-lymphocyte antigen-4 synergy. Moreover, PD-L1/PTX@HSA had low organ toxicity. Hence, the anti-tumor immune responses of PD-L1/PTX@HSA com- bined with chemotherapy and cytotoxic T-lymphocyte antigen-4 is a potential anti-tumor strategy for improving quantitative and qualitative clinical efficacy. | en_US |
dc.description.sponsorship | This work was supported by a National Research Fund (NRF) of Korea grant funded by the Korean Government (No. NRF- 2018R1A2B2004668, 2021R1A2C3009556) and by the Medical Research Center Program (No. 2015R1A5A2009124) through the NRF funded by MSIP. The authors thank the Core Research Support Center for Natural Products and Medical Materials (CRCNM) for technical support regarding the nano-indentation test. | en_US |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER | en_US |
dc.subject | Chemo-immunotherapy | en_US |
dc.subject | CTLA-4 | en_US |
dc.subject | Human serum albumin | en_US |
dc.subject | Nanoparticle albumin-bound | en_US |
dc.subject | Technology | en_US |
dc.subject | PD-L1 | en_US |
dc.subject | pH-sensitive | en_US |
dc.title | Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles | en_US |
dc.type | Article | en_US |
dc.relation.volume | 605 | - |
dc.identifier.doi | 10.1016/j.ijpharm.2021.120816 | - |
dc.relation.page | 2021-2033 | - |
dc.relation.journal | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.contributor.googleauthor | Pham, Le Minh | - |
dc.contributor.googleauthor | Poudel, Kishwor | - |
dc.contributor.googleauthor | Ou, Wenquan | - |
dc.contributor.googleauthor | Phung, Cao Dai | - |
dc.contributor.googleauthor | Nguyen, Hanh Thuy | - |
dc.contributor.googleauthor | Nguyen, Bao Loc | - |
dc.contributor.googleauthor | Karmacharya, Prajeena | - |
dc.contributor.googleauthor | Pandit, Mahesh | - |
dc.contributor.googleauthor | Chang, Jae-Hoon | - |
dc.contributor.googleauthor | Jeong, Jee-Heon | - |
dc.contributor.googleauthor | Ku, Sae Kwang | - |
dc.contributor.googleauthor | Yong, Chul Soon | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Kim, Jong Oh | - |
dc.relation.code | 2021004351 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.